Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14356/3083| Title: | A multicenter, randomized, double-blinded, placebo-controlled Phase III trial to evaluate the efficacy, safety and immunogenicity of the recombinant two-component COVID-19 vaccine (CHO cell) in adults aged 18 years and older |
| Authors: | Karki, Khem Bahadur Mo, Zhaojun |
| Issue Date: | 2022 |
| Publisher: | Society for Integrated Development Nepal (SOLID Nepal), Satdobato, Lalitpur, Nepal |
| Series/Report no.: | RES;01274 |
| Abstract: | NA |
| Description: | NHRC Approval |
| URI: | https://hdl.handle.net/20.500.14356/3083 |
| Appears in Collections: | Approval Research Report (NHRC) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| RES01274_KAR_2022.pdf | Download Full Report. | 22.11 MB | Adobe PDF |  View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.